Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Temozolomide in Elderly Newly-Diagnosed Glioblastoma
NCT01149850Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2010
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Apr 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01149850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149850.